Table 3.
Use of pharmacological and nonpharmacological treatments by COPD grouping at different visits (by class of treatment)
| Visit
|
Visit 1
|
Visit 2
|
Visit 3
|
|||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COPD group
|
A (n=5) | B (n=164) | C (n=8) | D (n=273) | A (n=4) | B (n=169) | C (n=1) | D (n=235) | A (n=3) | B (n=169) | C (n=3) | D (n=207) | ||||||||||||
|
|
|
|
||||||||||||||||||||||
| Drugs | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % |
| Any SABA | 5 | 100.0 | 156 | 95.1 | 8 | 100.0 | 266 | 97.4 | 3 | 75.0 | 147 | 87.0 | 1 | 100.0 | 210 | 89.4 | 3 | 100.0 | 156 | 92.3 | 3 | 100.0 | 198 | 95.7 |
| Any SAMA | 3 | 60.0 | 57 | 34.8 | 0 | 0.0 | 80 | 29.3 | 1 | 25.0 | 46 | 27.2 | 1 | 100.0 | 64 | 27.2 | 1 | 33.3 | 53 | 31.4 | 0 | 0.0 | 43 | 20.8 |
| LABA only | 1 | 20.0 | 1 | 0.6 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 0 | 0.0 | 1 | 100.0 | 3 | 1.3 | 1 | 33.3 | 2 | 1.2 | 0 | 0.0 | 2 | 1.0 |
| LAMA only | 0 | 0.0 | 6 | 3.7 | 0 | 0.0 | 6 | 2.2 | 0 | 0.0 | 1 | 0.6 | 0 | 0.0 | 4 | 1.7 | 0 | 0.0 | 2 | 1.2 | 0 | 0.0 | 3 | 1.4 |
| ICS only | 1 | 20.0 | 25 | 15.2 | 1 | 12.5 | 13 | 4.8 | 0 | 0.0 | 11 | 6.5 | 0 | 0.0 | 15 | 6.4 | 0 | 0.0 | 22 | 13.0 | 0 | 0.0 | 8 | 3.9 |
| Any LABA | 4 | 80.0 | 110 | 67.1 | 6 | 75.0 | 240 | 87.9 | 3 | 75.0 | 126 | 74.6 | 1 | 100.0 | 184 | 78.3 | 3 | 100.0 | 130 | 76.9 | 3 | 100.0 | 185 | 89.4 |
| Any LAMA | 2 | 40.0 | 82 | 50.0 | 7 | 87.5 | 174 | 63.7 | 2 | 50.0 | 88 | 52.1 | 0 | 0.0 | 136 | 57.9 | 2 | 66.7 | 90 | 53.3 | 3 | 100.0 | 149 | 72.0 |
| Any ICS | 4 | 80.0 | 144 | 87.8 | 8 | 100.0 | 262 | 96.0 | 3 | 75.0 | 147 | 87.0 | 0 | 0.0 | 202 | 86.0 | 2 | 66.7 | 152 | 89.9 | 3 | 100.0 | 193 | 93.2 |
| ICS + LABA | 1 | 20.0 | 43 | 26.2 | 0 | 0.0 | 81 | 29.7 | 1 | 25.0 | 49 | 29.0 | 0 | 0.0 | 57 | 24.3 | 0 | 0.0 | 46 | 27.2 | 0 | 0.0 | 43 | 20.8 |
| LABA + LAMA | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 2 | 0.9 | 0 | 0.0 | 4 | 2.4 | 0 | 0.0 | 4 | 1.9 |
| LABA + LAMA + ICS | 2 | 40.0 | 66 | 40.2 | 6 | 75.0 | 158 | 57.9 | 2 | 50.0 | 77 | 45.6 | 0 | 0.0 | 122 | 51.9 | 2 | 66.7 | 78 | 46.2 | 3 | 100.0 | 136 | 65.7 |
| LABA + LAMA + PDE4i | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 1 | 0.6 | 0 | 0.0 | 2 | 1.0 |
| Any theophylline | 1 | 20.0 | 44 | 26.8 | 2 | 25.0 | 76 | 27.8 | 1 | 25.0 | 53 | 31.4 | 0 | 0.0 | 52 | 22.1 | 1 | 33.3 | 42 | 24.9 | 0 | 0.0 | 55 | 26.6 |
| Any PDE4i | 1 | 20.0 | 0 | 0.0 | 0 | 0.0 | 17 | 6.2 | 0 | 0.0 | 9 | 5.3 | 0 | 0.0 | 10 | 4.3 | 0 | 0.0 | 5 | 3.0 | 0 | 0.0 | 21 | 10.1 |
| Any montelukast | 0 | 0.0 | 1 | 0.6 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
Abbreviations: ICS, inhaled corticosteroids; ICS + LABA, LABA with ICS together in single or separate inhaler devices; LABA, long-acting (32-agonist; LABA + LAMA, LABA with LAMA together in single or separate inhaler devices; LABA + LAMA + ICS, LABA, LAMA and ICS together in single or separate devices; LABA + LAMA + PDE4i, LABA and LAMA together in single or separate inhaler device with PDE4i; LAMA, long-acting muscarinic antagonist; PDE4i, phosphodiesterase 4 inhibitors; SABA, short-acting (32-agonist; SAM A, short-acting muscarinic antagonist.